A. Gilsenan

First name
A.
Last name
Gilsenan
Johannes, C. B., Beachler, D. C., Layton, J. B., Danysh, H. E., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3
View
Danysh, H. E., Johannes, C. B., Beachler, D. C., Layton, J. B., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4
View
Fortuny, J., Gilsenan, A., Cainzos-Achirica, M., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L., et al. (2019). Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350. Drug Saf. http://doi.org/10.1007/s40264-019-00836-z
View
Gilsenan, A., Fortuny, J., Cainzos-Achirica, M., Cantero, O. F., Flynn, R. W. V., Garcia-Rodriguez, L., et al. (2019). Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-019-00835-0
View
Arana, A., Margulis, A. V., Varas-Lorenzo, C., Bui, C. L., Gilsenan, A., McQuay, L. J., et al. (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150
View
Ruigomez, A., Plana, E., Gilsenan, A., Fortuny, J., Cainzos-Achirica, M., Flynn, R. W. V., et al. (2021). Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride. Drug Saf. http://doi.org/10.1007/s40264-021-01044-4
View